Autres langues Sensei Biotherapeutics, Inc.

Actions

SNSE

US81728A1088

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,02 ^USD	+1,99 %		+5,15 %	+47,40 %

24/04	Sensei Biotherapeutics présentera les principales données cliniques de l'étude de phase I SNS-101 lors de la réunion annuelle de l'ASCO en 2024	CI
04/04	Sensei Biotherapeutics annonce la publication dans Nature Communications d'un article décrivant le mécanisme d'action du SNS-101 qui cible sélectivement la forme active de Vista dans le microenvironnement tumoral	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference	09/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment	04/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	04/04
Sensei Biotherapeutics : Company Presentation April 2024	02/04
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	02/04
North American Morning Briefing : Stocks Set for -2-	28/03
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium	22/03
Keystone Symposia 2024: Preclinical data for SNS-101	21/03
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences	06/03
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	28/02
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Sensei Biotherapeutics, Inc. Announces Management Changes	08/02
Sensei Biotherapeutics to Present at Upcoming Conferences	07/02
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones	04/01
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	07/11
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights	07/11
Sensei Biotherapeutics : Regulation FD Disclosure - Form 8-K	06/11
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..	06/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

SENSEI BIOTHERAPEUTICS : Un troisième trimestre contrasté, mais une trésorerie intacte

Le 10 novembre 2022 à 12:59